A patent family can become its own most dangerous prior art, and most pharmaceutical patent teams discover this too late to address it.
The drafting logic that creates the problem is entirely understandable at the time the first decision is made. The first application is filed broadly because the full commercial potential of the technology is not yet mapped and maximum coverage feels like the prudent choice. Years of development later, one compound emerges as commercially decisive. A second application is filed to protect it specifically. Then the first application returns with a question the portfolio was not designed to answer. If the broad genus claim already covers the selected compound, what has the second application disclosed that is actually new?
On 6 July 2026, the Delhi High Court answered that question in Intra Cellular Therapies Inc. v. Controller of Patents and Designs in a way that reshapes pharmaceutical patent portfolio strategy well before Indian examination begins. The decision links genus coverage, species novelty and therapeutic efficacy proof under Section 3(d) in a framework that global patent committees and research teams, not only Indian prosecution counsel, need to read and act on.
What the Court Decided and the Proposition That Drives It
The application concerned deuterated compounds for the treatment of central nervous system disorders. Deuteration, the substitution of hydrogen atoms with deuterium isotopes, can alter the metabolic profile of a known compound in ways that may produce clinically relevant differences in pharmacokinetics or pharmacodynamics. The applicant sought to protect specific deuterated variants of compounds that had been described at the genus level in earlier patent filings.
The Controller rejected the claims on three grounds: lack of novelty, lack of inventive step and non patentability under Section 3(d) of the Patents Act, 1970. The Delhi High Court upheld the novelty and Section 3(d) rejections. Because both were upheld, the Court did not find it necessary to reach the inventive step question.
The novelty holding rests on a proposition that is more consequential than any individual case outcome. The applicant argued that multiple selections were required to arrive at the specific deuterated compounds claimed, and that this selectivity should create novelty over the genus. The Court rejected that argument by applying established Delhi High Court precedent. When a product is covered by the claims of an earlier patent, the absence of a separate specific disclosure of that product in the earlier patent is immaterial to the novelty analysis.
The reach of that proposition is significant. It means that a genus claim broad enough to read on a specific compound for infringement purposes is also, on this analysis, a disclosure that can defeat a subsequent application for that compound on novelty grounds. The coverage that makes the genus valuable becomes the coverage that creates the novelty barrier for the follow on application. Portfolio teams that have argued broad genus coverage in infringement proceedings and then sought narrow species protection in separate prosecution proceedings are operating on a collision course that the Intra Cellular Therapies decision has now mapped clearly.
The Section 3(d) Standard and Its Evidentiary Demands
The Section 3(d) holding in Intra Cellular Therapies addresses the evidentiary standard that applies when a pharmaceutical applicant seeks to distinguish a new form of a known substance by relying on pharmacokinetic or pharmacodynamic data. The standard the Court applies is demanding and its demands should be understood precisely.
Section 3(d) bars patents for new forms of known substances unless the applicant demonstrates significantly enhanced efficacy. For deuterated compounds, the known substance is the undeuterated parent and the new form is the deuterated variant. The question is whether the differences in metabolic profile produced by deuteration constitute significantly enhanced efficacy within the meaning of the statute.
The applicant relied on pharmacokinetic data demonstrating substantially higher parent drug exposure under one route of administration and changes in metabolite formation compared to the undeuterated compound. The Court held this was insufficient to satisfy Section 3(d). The reason is precise and should not be generalised beyond its specific content. Improved bioavailability, measured as increased plasma drug exposure, does not by itself establish enhanced therapeutic efficacy. The pharmacokinetic improvement must be shown to translate into a therapeutic benefit, meaning a measurable clinical outcome relevant to the therapeutic indication for which the compound is being developed.
The ruling does not hold that bioavailability data can never support a Section 3(d) case. It holds that pharmacokinetic data that is not connected to a demonstrated therapeutic consequence does not complete the statutory bridge Section 3(d) requires. The applicant must show not only that the pharmacokinetic profile of the new form differs from the known substance but that the difference in profile produces a difference in therapeutic outcome that is clinically meaningful.
This distinction matters practically for how the efficacy package is assembled. The pharmacokinetic data must be supplemented by evidence connecting the measured property to the therapeutic claim. That evidence must be present in the specification as filed, because later evidence asked to supply a missing invention rather than to support what the specification teaches is treated very differently in Indian proceedings than data that the specification relies on directly.
The Drafting Dilemma That Cannot Be Deferred
The Intra Cellular Therapies decision forces a confrontation with a drafting dilemma that pharmaceutical patent teams typically encounter years into prosecution rather than at the filing stage, and the decision makes clear that the consequences of that deferral are not recoverable.
The dilemma is structural. A broad genus claim that covers large chemical space is commercially valuable in enforcement because it can be read to cover competitor products without requiring those products to be specifically identified or exemplified in the original specification. The same breadth becomes a commercial liability when the portfolio seeks to protect a species within that genus, because the genus coverage that the enforcement strategy relies on is also the disclosure that defeats the follow on application.
Patent law does not treat coverage and disclosure as identical in all contexts. There are doctrinal frameworks in which a claim broad enough to read on a product is not treated as an enabling disclosure of that product for novelty purposes. The Intra Cellular Therapies decision, following earlier Delhi High Court authority, takes a position on this question that is adverse to the applicant seeking to distinguish coverage from disclosure for novelty purposes. The portfolio must be drafted on the assumption that this position will apply when the relationship between the genus and the species is tested in Indian prosecution.
The practical consequence is that the decision about which compounds to exemplify in the genus specification, how to structure the selection pathways from the genus to commercially important species, and how to time and structure follow on applications is a decision that must be made before the genus application is filed, not after the species application is rejected.
Questions That Should Be Answered Before the Genus Application Is Filed
The decision points to specific questions that every pharmaceutical and chemical patent team should address at the genus drafting stage. Most of these questions are currently being deferred until the follow on application is in prosecution, by which time the genus disclosure is fixed and the options for addressing the novelty problem are severely constrained.
The first question is which species, substitution patterns, salt forms, polymorphs and formulation variants are most likely to be commercially important during the life of the patent. The answer should inform not only the scope of the genus claims but the selection of compounds for exemplification in the specification. Compounds that are likely to be commercially important should be expressly exemplified, with the rationale for their selection explained, rather than simply encompassed within a broad claim.
The second question is whether the specification provides reasoned pathways from the genus to the commercially important species. A specification that describes an undifferentiated universe of compounds encompassed by the claim, with minimal exemplification and no guidance on how to identify the preferred compounds, provides weak support for the proposition that specific species were technically taught by the disclosure. A specification that exemplifies the commercially important compounds and explains the basis for their properties creates a stronger foundation both for the genus claims and for follow on applications.
The third question is whether the breadth of the genus claims could become a novelty barrier for a follow on application. If the genus claim is drafted to cover the compound that will be the subject of the follow on application, the Intra Cellular Therapies analysis should be applied to assess whether the follow on novelty case is viable on those facts. If it is not, the portfolio strategy must address this before the genus application is published.
The fourth question is whether the follow on filing strategy is mapped and calendar ready before the genus application is published. Once the genus application is published, it becomes available as prior art. A follow on application that establishes its priority date before the genus publication avoids the novelty problem entirely. The species application that is filed after the genus publication faces the full force of the Intra Cellular Therapies analysis. Filing strategy decisions that could have been made before publication become irrecoverable after it.
The Broader Conversation the Decision Should Start
The Intra Cellular Therapies decision raises a doctrinal question that deserves engagement beyond the specific context of deuterated compounds and Section 3(d).
When a genus claim is broad enough to cover a specific compound for the purposes of an infringement action, should that always mean the compound was disclosed for the purposes of a novelty analysis in a subsequent application? The answer that the Court applies in this case is yes. But the question is not settled universally. There are jurisdictions and doctrinal frameworks that treat coverage and disclosure as analytically distinct, preserving the ability to argue that a claim broad enough to read on a product did not specifically disclose it in a technically enabling sense.
The value of preserving that distinction is not merely theoretical. It is the distinction that allows a pharmaceutical portfolio to provide broad coverage against competitor products while retaining the ability to secure follow on protection for the specific compounds that prove commercially decisive. If coverage and disclosure are treated as coextensive, the portfolio must choose between broad coverage now and follow on protection later. That is a commercially significant constraint and one that deserves serious debate in the Indian patent community.
The easy response to Intra Cellular Therapies is to treat it as another application of Section 3(d) strictness and adjust the efficacy data package accordingly. The more consequential response is to engage with the genus coverage and species novelty relationship directly, to build drafting strategies that account for it from day one, and to contribute to the debate about whether Indian patent law should develop a sharper distinction between legal coverage and technical teaching.
That is the conversation this decision should start, and it should happen in research teams and global patent committees, not only in Indian prosecution files.
